Thermal Gradient has officially graduated from its status as an incubation-phase startup business resident at High Tech Rochester’s BioVenture Center.
Started by Dr. Joel Grover as CEO and Bob Juncosa as chief technology officer — former managers at Ortho Clinical Diagnostic — Thermal Gradient signed on for residency in the RBC in 2008.
The company’s goal is to become the most vital strategic development partner for the molecular diagnostic industry, which provides specialized testing equipment for clinical laboratories used in hospitals for diagnostic testing. Thermal Gradient has four issued and three pending patents for its core technology.
Thermal Gradient recently signed an agreement with Axela Inc. of Toronto to integrate its “Ultra Fast PCR” technology with Axela’s products for creation of a new, simplified and rapid molecular diagnostic system. The company is in discussions with other firms desiring access to Thermal Gradient’s technology. Thermal Gradient was also a recent recipient of a multi-year grant from the National Institutes of Health for the continuing development of its HIV diagnostic system.